Results for: NRx Pharmaceuticals

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, is expanding its mental health treatment offerings by acquiring a network of interventional psychiatry clinics specializing in ketamine therapies. The acquisition, valued at $30 million, aims to create a unified patient-centered approach combining pharmaceutical therapies and FDA-approved technologies.

NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, announced securing up to $16 million in financing to advance its two lead products, NRX-100 and NRX-101, for the treatment of suicidal depression. The financing will also allow the company to retire existing debt from Streeterville Capital.